ClinicalTrials.gg
CompletedNCT01830855Updated Jun 14, 2016Results posted

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

A Phase 3 interventional study of rLP2086 and rLP2086 in Meningococcal Vaccine, sponsored by Pfizer. Completed at 99 sites in 8 countries. Open to participants aged 10 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-14.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,596
Allocation
Randomized
Ages
10 Years to 18 Years
Sex
All
01

Study summary

This study is looking at a new vaccine that might prevent meningococcal disease, and will study whether healthy adolescent subjects receiving different lots of vaccine respond in a similar way. The study will also look at the safety of the new vaccine as well as how it is tolerated.

02

Conditions studied

  • Meningococcal Vaccine
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subject aged >=10 and \<19 years at the time of enrollment.
  2. Healthy subject as determined by medical history, physical examination, and judgment of the investigator.
  3. Negative urine pregnancy test for all female subjects.

Exclusion criteria

Exclusion Criteria:

  1. Previous vaccination with any meningococcal serogroup B vaccine.
  2. Subjects who have received prior HAV vaccination.
  3. Subjects who are scheduled to receive 1 or more doses of an HPV vaccine as part of a 3-dose series during the period between Visit 1 and 28 days after the second vaccination.
  4. Subjects receiving any allergen immunotherapy with a nonlicensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses.
  5. A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) therapy, or those receiving therapy. Subjects in the United States with terminal complement deficiency are excluded from participation in this study.
  6. Significant neurological disorder or history of seizure (excluding simple febrile seizure).
  7. Current chronic use of systemic antibiotics.
  8. Received any vaccines, drugs, or devices within 28 days before administration of the first study vaccination.
  9. Any neuroinflammatory or condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,596 participants (actual)

Study arms

  • Experimental
    rLP2086 lot 1

    Biological: rLP2086

  • Experimental
    rLP2086 lot 2

    Biological: rLP2086

  • Experimental
    rLP2086 lot 3

    Biological: rLP2086

  • Active comparator
    Control

    Havrix (HAV) and Saline

    Biological: Havrix (HAV) · Biological: Saline

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With >=4 Fold Rise in Serum Bactericidal Assay Using Human Complement (hSBA) for 4 Primary Strains and Composite Response (hSBA >=Lower Limit of Quantification [LLOQ] for All 4 Primary Strains Combined) for Group 1

    Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1,2,3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA. Here, N signifies participants with valid and determinate hSBA titers for given strain at specified time point.

    Time frame: One month after third bivalent rLP2086 vaccination

  2. hSBA Geometric Mean Titers (GMTs) for Each of the 2 Primary Test Strains Measured 1 Month After the Third Vaccination With Bivalent rLP2086 Vaccine

    Time frame: One month after third bivalent rLP2086 vaccination

  3. Percentage of Participants Reporting Local Reactions (LRs) Within 7 Days After First Vaccination

    Time frame: Within 7 Days after first vaccination

  4. Percentage of Participants Reporting Local Reactions (LRs) Within 7 Days After Second Vaccination

    Time frame: Within 7 Days after second vaccination

  5. Percentage of Participants Reporting Local Reactions (LRs) Within 7 Days After Third Vaccination

    Time frame: Within 7 Days after third vaccination

  6. Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After First Vaccination

    Here, N signifies participants with known values reporting specific characteristic.

    Time frame: Within 7 Days after first vaccination

  7. Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Second Vaccination

    Here, N signifies participants with known values reporting specific characteristic.

    Time frame: Within 7 Days after second vaccination

  8. Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Third Vaccination

    Here, N signifies participants with known values reporting specific characteristic.

    Time frame: Within 7 Days after third vaccination

  9. Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After First Vaccination

    Time frame: Within 30 days after first vaccination

  10. Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Second Vaccination

    Time frame: Within 30 days after second vaccination

  11. Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Third Vaccination

    Time frame: Within 30 days after third vaccination

  12. Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Any Vaccination

    Time frame: Within 30 days after any vaccination

  13. Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Vaccination Phase

    Time frame: From the first vaccination up to 1 month after the third vaccination

  14. Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Follow-Up Phase

    Time frame: From 1 month after third vaccination up to 6 months after the third vaccination

  15. Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Throughout the Study Period

    Time frame: From the first vaccination up to 6 month after the third vaccination

  16. Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After First Vaccination

    Time frame: Within 30 days after first vaccination

  17. Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Second Vaccination

    Time frame: Within 30 days after second vaccination

  18. Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Third Vaccination

    Time frame: Within 30 days after third vaccination

  19. Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination

    Time frame: Within 30 days after any vaccination

  20. Percentage of Participants With at Least 1 Medically Attended AE During the Vaccination Phase

    Time frame: From the first vaccination up to 1 month after the third vaccination

  21. Percentage of Participants With at Least 1 Medically Attended AE During the Follow-Up Phase

    Time frame: From 1 month after third vaccination up to 6 months after the third vaccination

  22. Percentage of Participants With at Least 1 Medically Attended AE Throughout the Study Period

    Time frame: From the first vaccination up to 6 month after the third vaccination

  23. Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After First Vaccination

    Time frame: Within 30 days after first vaccination

  24. Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Second Vaccination

    Time frame: 30 days after second vaccination

  25. Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Third Vaccination

    Time frame: Within 30 days after third vaccination

  26. Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Any Vaccination

    Time frame: Within 30 Days After any Vaccination

  27. Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Vaccination Phase

    Time frame: From the first vaccination up to 1 month after the third vaccination

  28. Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Follow-Up Phase

    Time frame: From 1 month after third vaccination up to 6 months after the third vaccination

  29. Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Throughout the Study Period

    Time frame: From the first vaccination up to 6 month after the third vaccination

  30. Percentage of Participants With at Least 1 Adverse Event (AE) WIthin 30 Days After First Vaccination

    Time frame: Within 30 days after first vaccination

  31. Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Second Vaccination

    Time frame: Within 30 days after second vaccination

  32. Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Third Vaccination

    Time frame: Within 30 days after third vaccination

  33. Percentage of Participants With at Least 1 Adverse Event Within 30 Days After Any Vaccination

    Time frame: Within 30 Days after any vaccination

  34. Percentage of Participants With at Least 1 Adverse Event During the Vaccination Phase

    Time frame: From the first vaccination up to 1 month after the third vaccination

  35. Percentage of Participants Reporting at Least 1 Immediate AE After First Vaccination

    Time frame: Within 30 minutes after first vaccination

  36. Percentage of Participants Reporting at Least 1 Immediate AE After Second Vaccination

    Time frame: Within 30 minutes after second vaccination

  37. Percentage of Participants Reporting at Least 1 Immediate AE After Third Vaccination

    Time frame: Within 30 minutes after third vaccination

  38. Number of Days Participant's Missed School or Work Due to AE During the Vaccination Phase

    Time frame: From the first vaccination up to 1 month after the third vaccination

Secondary outcomes

  1. Percentage of Participants With hSBA Titers >=LLOQ for 10 Secondary Strains Before First Vaccination and 1 Month After Third Bivalent rLP2086 Vaccination for Group 1

    Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2, 3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.

    Time frame: Before first vaccination, 1 month after third vaccination

  2. Percentage of Participants With hSBA Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, >=1:128 for Each of the 10 Secondary Strains, Before Vaccination 1 and 1 Month After the Third Bivalent rLP2086 Vaccination for Group 1

    Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2, 3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.

    Time frame: Before first vaccination, 1 month after third vaccination (Vac)

  3. hSBA Geometric Mean Titers (GMTs) for Each of the 10 Secondary Strains Before First Vaccination and 1 Month After the Third Bivalent rLP2086 Vaccination for Group 1

    Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2, 3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.

    Time frame: Before first vaccination, 1 month after third vaccination

  4. Percentage of Participants Achieving Composite hSBA Titer >=Lower Limit of Quantitation for All 4 Primary Strains Before First Vaccination and 1 Month After Second Bivalent rLP2086 Vaccination for Group 1

    Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2 ,3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.

    Time frame: Before vaccination 1, 1 Month after Vaccination 2

  5. Percentage of Participants Achieving at Least a 4-Fold Increase in hSBA Titer for Each of the 4 Primary Strains Before First Vaccination to 1 Month After the Second Bivalent rLP2086 Vaccination for Group 1

    Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2, 3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.

    Time frame: One month after second Bivalent rLP2086 vaccination

  6. Percentage of Participants Achieving at Least a 4-Fold Increase in hSBA Titer for 2 Primary Strains Before First Vaccination to 1 Month After the Second and Third Bivalent rLP2086 Vaccination

    Time frame: One month after second, third vaccination

  7. hSBA Geometric Mean Titers (GMTs) for 4 Primary Test Strains and for 2 Primary Test Strains and Before First Vaccination and 1 Month After the Second Bivalent rLP2086 Vaccination

    Time frame: Before vaccination (Vac) 1, 1 Month after Vac 2

  8. Percentage of Participants With hSBA Titers >=LLOQ for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination

    Time frame: Before Vaccination (Vac) 1, 1 Month after Vac 2, 3

  9. Percentage of Participants With hSBA Titers >=1:4,>=1:8,>=1:16,>=1:32,>=1:64,>=1:128 for Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination

    Results for PMB80\[A22\] 1:16, PMB2001\[A56\] 1:8, PMB2948\[B24\] 1:8 and PMB2707\[B44\] 1:8 are reported under secondary outcome measure 'Percentage of Participants With hSBA Titers \>=LLOQ for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination.

    Time frame: Before Vaccination (Vac) 1, 1 Month after Vac 2, 3

  10. Percentage of Participants Achieving at Least a 3-Fold Increase in hSBA Titer for 4 Primary Test Strains and for Primary Test Starins Before First Vaccination to 1 Month After Third Bivalent rLP2086 Vaccination

    Time frame: One month after third bivalent rLP2086 vaccination

  11. Percentage of Participants Achieving at Least a 2-Fold Increase in hSBA Titer for 4 Primary Test Strains and for 2 Primary Test Starins Before First Vaccination to 1 Month After the Third Bivalent rLP2086 Vaccination

    Time frame: One month after third bivalent rLP2086 vaccination (Vac)

07

Results

Posted Jun 14, 2016

Participant flow

Participant flow — Overall Study
MilestoneGroup 1 rLP2086 Lot 1Group 2 rLP2086 Lot 2Group 3 rLP2086 Lot 3Group 4 HAV/Saline
Started1508598587897
Completed1353537521815
Not completed155616682
Withdrew: Other7144
Withdrew: Medication error without associated ae1001
Withdrew: Pregnancy3121
Withdrew: No longer meets eligibility criteria11235
Withdrew: Adverse event11563
Withdrew: Protocol deviation10566
Withdrew: Withdrawal by subject33141012
Withdrew: No longer willing to participate32131217
Withdrew: Lost to follow-up47202333

Outcome measures

PrimaryPercentage of Participants With >=4 Fold Rise in Serum Bactericidal Assay Using Human Complement (hSBA) for 4 Primary Strains and Composite Response (hSBA >=Lower Limit of Quantification [LLOQ] for All 4 Primary Strains Combined) for Group 1

Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1,2,3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA. Here, N signifies participants with valid and determinate hSBA titers for given strain at specified time point.

Time frame:
One month after third bivalent rLP2086 vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With >=4 Fold Rise in Serum Bactericidal Assay Using Human Complement (hSBA) for 4 Primary Strains and Composite Response (hSBA >=Lower Limit of Quantification [LLOQ] for All 4 Primary Strains Combined) for Group 1
percentage of participantsGroup 1 rLP2086 Lot 1
Composite hSBA response (N= 1170)83.5 (81.3 to 85.6)
PMB80[A22] (N= 1225)83.2 (81.0 to 85.2)
PMB2001[A56] (N= 1128)90.2 (88.4 to 91.9)
PMB2948[B24] (N= 1235)79.8 (77.4 to 82.0)
PMB2707[B44] (N= 1203)85.9 (83.8 to 87.8)
PrimaryhSBA Geometric Mean Titers (GMTs) for Each of the 2 Primary Test Strains Measured 1 Month After the Third Vaccination With Bivalent rLP2086 Vaccine
Time frame:
One month after third bivalent rLP2086 vaccination
Reported as:
Geometric mean · titer
hSBA Geometric Mean Titers (GMTs) for Each of the 2 Primary Test Strains Measured 1 Month After the Third Vaccination With Bivalent rLP2086 Vaccine
titerGroup 1 rLP2086 Lot 1Group 2 rLP2086 Lot 2Group 3 rLP2086 Lot 3
PMB80[A22] (N= 1266, 518, 492)86.8 (82.29 to 91.50)84.3 (77.54 to 91.68)85.1 (78.26 to 92.47)
PMB2948[B24] (N= 1250, 516, 479)24.1 (22.70 to 25.48)25.3 (23.08 to 27.72)25.2 (23.03 to 27.58)
Statistical analysis
  • Group 1 rLP2086 Lot 1 vs Group 2 rLP2086 Lot 2 · Ratio of gmts: 1.03 · 95% CI 0.93 to 1.14
  • Group 1 rLP2086 Lot 1 vs Group 3 rLP2086 Lot 3 · Ratio of gmts: 1.02 · 95% CI 0.92 to 1.13
  • Group 2 rLP2086 Lot 2 vs Group 3 rLP2086 Lot 3 · Ratio of gmts: 0.99 · 95% CI 0.88 to 1.12
  • Group 1 rLP2086 Lot 1 vs Group 2 rLP2086 Lot 2 · Ratio of gmts: 0.95 · 95% CI 0.85 to 1.06
  • Group 1 rLP2086 Lot 1 vs Group 3 rLP2086 Lot 3 · Ratio of gmts: 0.95 · 95% CI 0.86 to 1.06
  • Group 2 rLP2086 Lot 2 vs Group 3 rLP2086 Lot 3 · Ratio of gmts: 1.00 · 95% CI 0.88 to 1.14
PrimaryPercentage of Participants Reporting Local Reactions (LRs) Within 7 Days After First Vaccination
Time frame:
Within 7 Days after first vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Local Reactions (LRs) Within 7 Days After First Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Pain at injection site: Any86.7 (85.4 to 88.0)47.0 (43.6 to 50.3)
Pain at injection site: Mild41.1 (39.2 to 43.0)36.5 (33.3 to 39.8)
Pain at injection site: Moderate40.7 (38.8 to 42.5)9.9 (8.0 to 12.0)
Pain at injection site: Severe5.0 (4.2 to 5.9)0.6 (0.2 to 1.3)
Redness: Any16.2 (14.8 to 17.7)1.3 (0.7 to 2.3)
Redness: Mild5.6 (4.7 to 6.5)1.2 (0.6 to 2.2)
Redness: Moderate8.8 (7.7 to 9.9)0.1 (0.0 to 0.6)
Redness: Severe1.9 (1.4 to 2.5)0.0 (0.0 to 0.4)
Swelling: Any18.0 (16.5 to 19.5)2.2 (1.4 to 3.4)
Swelling: Mild8.5 (7.4 to 9.6)1.8 (1.0 to 2.9)
Swelling: Moderate8.8 (7.7 to 9.9)0.4 (0.1 to 1.1)
Swelling: Severe0.7 (0.5 to 1.1)0.0 (0.0 to 0.4)
PrimaryPercentage of Participants Reporting Local Reactions (LRs) Within 7 Days After Second Vaccination
Time frame:
Within 7 Days after second vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Local Reactions (LRs) Within 7 Days After Second Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Pain at injection site: Any77.7 (76.0 to 79.3)15.2 (12.8 to 17.8)
Pain at injection site: Mild39.4 (37.5 to 41.3)12.3 (10.2 to 14.7)
Pain at injection site: Moderate33.2 (31.4 to 35.1)2.7 (1.7 to 4.1)
Pain at injection site: Severe5.1 (4.2 to 6.0)0.1 (0.0 to 0.7)
Redness: Any12.5 (11.2 to 13.8)0.6 (0.2 to 1.4)
Redness: Mild5.2 (4.4 to 6.2)0.6 (0.2 to 1.4)
Redness: Moderate6.1 (5.2 to 7.1)0.0 (0.0 to 0.4)
Redness: Severe1.1 (0.8 to 1.6)0.0 (0.0 to 0.4)
Swelling: Any13.9 (12.5 to 15.3)0.6 (0.2 to 1.4)
Swelling: Mild6.3 (5.4 to 7.3)0.5 (0.1 to 1.2)
Swelling: Moderate7.3 (6.4 to 8.4)0.1 (0.0 to 0.7)
Swelling: Severe0.2 (0.1 to 0.5)0.0 (0.0 to 0.4)
PrimaryPercentage of Participants Reporting Local Reactions (LRs) Within 7 Days After Third Vaccination
Time frame:
Within 7 Days after third vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Local Reactions (LRs) Within 7 Days After Third Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Pain at injection site: Any76.0 (74.2 to 77.7)34.0 (30.7 to 37.3)
Pain at injection site: Mild34.1 (32.2 to 36.0)23.8 (20.9 to 26.8)
Pain at injection site: Moderate36.5 (34.6 to 38.5)9.9 (7.9 to 12.1)
Pain at injection site: Severe5.4 (4.5 to 6.4)0.4 (0.1 to 1.1)
Redness: Any13.9 (12.5 to 15.3)1.1 (0.5 to 2.1)
Redness: Mild4.9 (4.1 to 5.8)1.0 (0.4 to 1.9)
Redness: Moderate6.8 (5.8 to 7.9)0.1 (0.0 to 0.7)
Redness: Severe2.2 (1.6 to 2.9)0.0 (0.0 to 0.4)
Swelling: Any15.4 (14.0 to 16.9)0.9 (0.3 to 1.7)
Swelling: Mild7.9 (6.8 to 9.0)0.7 (0.3 to 1.6)
Swelling: Moderate6.8 (5.8 to 7.9)0.1 (0.0 to 0.7)
Swelling: Severe0.7 (0.4 to 1.1)0.0 (0.0 to 0.4)
PrimaryPercentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After First Vaccination

Here, N signifies participants with known values reporting specific characteristic.

Time frame:
Within 7 Days after first vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After First Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Fever >=38 degrees C(N=2679, 890)6.4 (5.5 to 7.4)1.9 (1.1 to 3.0)
Fever 38 to <38.5 degreesC(N=2679, 890)4.0 (3.3 to 4.8)1.3 (0.7 to 2.3)
Fever 38.5 to<39 degrees C(N=2679, 890)1.9 (1.5 to 2.5)0.3 (0.1 to 1.0)
Fever 39 to 40 degrees C(N=2679, 890)0.5 (0.3 to 0.8)0.2 (0.0 to 0.8)
Fever >40 degrees C(N=2679, 890)0.0 (0.0 to 0.1)0.0 (0.0 to 0.4)
Vomiting:Any(N=2681,890)3.7 (3.0 to 4.5)1.9 (1.1 to 3.0)
Vomiting:Mild(N=2681,890)2.8 (2.2 to 3.5)1.7 (0.9 to 2.8)
Vomiting:Moderate(N=2681,890)0.9 (0.6 to 1.4)0.2 (0.0 to 0.8)
Vomiting:Severe(N=2681,890)0.0 (0.0 to 0.1)0.0 (0.0 to 0.4)
Diarrhea:Any(N=2681,890)10.6 (9.5 to 11.9)12.1 (10.1 to 14.5)
Diarrhea:Mild(N=2681,890)9.1 (8.0 to 10.3)10.9 (8.9 to 13.1)
Diarrhea:Moderate(N=2681,890)1.3 (0.9 to 1.8)1.1 (0.5 to 2.1)
Diarrhea:Severe(N=2681,890)0.3 (0.1 to 0.5)0.1 (0.0 to 0.6)
Headache:Any(N=2681,890)51.8 (49.9 to 53.8)37.2 (34.0 to 40.5)
Headache:Mild(N=2681,890)28.7 (27.0 to 30.5)24.0 (21.3 to 27.0)
Headache:Moderate(N=2681,890)21.0 (19.4 to 22.6)12.5 (10.4 to 14.8)
Headache:Severe(N=2681,890)2.2 (1.6 to 2.8)0.7 (0.2 to 1.5)
Fatigue:Any(N=2681,890)54.0 (52.1 to 55.9)40.3 (37.1 to 43.6)
Fatigue:Mild(N=2681,890)27.8 (26.1 to 29.5)23.5 (20.7 to 26.4)
Fatigue:Moderate(N=2681,890)23.2 (21.6 to 24.8)15.2 (12.9 to 17.7)
Fatigue:Severe(N=2681,890)3.0 (2.4 to 3.7)1.7 (0.9 to 2.8)
Chills:Any(N=2681,890)25.3 (23.7 to 27.0)17.2 (14.8 to 19.8)
Chills:Mild(N=2681,890)16.2 (14.8 to 17.6)13.3 (11.1 to 15.7)
Chills:Moderate(N=2681,890)8.0 (7.0 to 9.1)3.5 (2.4 to 4.9)
Chills:Severe(N=2681,890)1.2 (0.8 to 1.7)0.4 (0.1 to 1.1)
Muscle pain:Any(N=2681,890)24.4 (22.8 to 26.1)19.2 (16.7 to 22.0)
Muscle pain:Mild(N=2681,890)13.2 (11.9 to 14.5)13.5 (11.3 to 15.9)
Muscle pain:Moderate(N=2681,890)10.1 (9.0 to 11.3)5.4 (4.0 to 7.1)
Muscle pain:Severe(N=2681,890)1.2 (0.8 to 1.6)0.3 (0.1 to 1.0)
Joint pain:Any(N=2681,890)21.9 (20.4 to 23.5)13.6 (11.4 to 16.0)
Joint pain:Mild(N=2681,890)11.8 (10.6 to 13.1)8.3 (6.6 to 10.3)
Joint pain:Moderate(N=2681,890)8.7 (7.7 to 9.8)4.6 (3.3 to 6.2)
Joint pain:Severe(N=2681,890)1.4 (1.0 to 1.9)0.7 (0.2 to 1.5)
Antipyretic medication(N=2681,890)20.7 (19.2 to 22.3)10.4 (8.5 to 12.6)
PrimaryPercentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Second Vaccination

Here, N signifies participants with known values reporting specific characteristic.

Time frame:
Within 7 Days after second vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Second Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Fever >=38 degrees C(N=2540, 840)2.0 (1.5 to 2.6)1.5 (0.8 to 2.6)
Fever 38 to <38.5 degreesC(N=2540, 840)1.2 (0.8 to 1.7)0.7 (0.3 to 1.5)
Fever 38.5 to<39 degrees C(N=2540, 840)0.7 (0.4 to 1.1)0.7 (0.3 to 1.5)
Fever 39 to 40 degrees C(N=2540, 840)0.1 (0.0 to 0.3)0.1 (0.0 to 0.7)
Fever >40 degrees C(N=2540, 840)0.0 (0.0 to 0.1)0.0 (0.0 to 0.4)
Vomiting:Any(N=2545, 843)2.2 (1.6 to 2.8)1.4 (0.7 to 2.5)
Vomiting:Mild(N=2545, 843)1.7 (1.3 to 2.3)1.1 (0.5 to 2.0)
Vomiting:Moderate(N=2545, 843)0.4 (0.2 to 0.8)0.4 (0.1 to 1.0)
Vomiting:Severe(N=2545, 843)0.0 (0.0 to 0.1)0.0 (0.0 to 0.4)
Diarrhea:Any(N=2545, 843)7.6 (6.6 to 8.7)9.1 (7.3 to 11.3)
Diarrhea:Mild(N=2545, 843)6.2 (5.3 to 7.2)7.6 (5.9 to 9.6)
Diarrhea:Moderate(N=2545, 843)1.3 (0.9 to 1.8)1.2 (0.6 to 2.2)
Diarrhea:Severe(N=2545, 843)0.1 (0.0 to 0.3)0.4 (0.1 to 1.0)
Headache:Any(N=2545, 843)37.8 (35.9 to 39.8)28.1 (25.1 to 31.3)
Headache:Mild(N=2545, 843)20.2 (18.7 to 21.8)15.7 (13.3 to 18.3)
Headache:Moderate(N=2545, 843)16.0 (14.6 to 17.5)10.9 (8.9 to 13.2)
Headache:Severe(N=2545, 843)1.7 (1.2 to 2.2)1.5 (0.8 to 2.6)
Fatigue:Any(N=2545, 843)38.3 (36.4 to 40.2)26.3 (23.4 to 29.4)
Fatigue:Mild(N=2545, 843)20.6 (19.0 to 22.2)13.2 (11.0 to 15.6)
Fatigue:Moderate(N=2545, 843)15.8 (14.4 to 17.3)11.7 (9.6 to 14.1)
Fatigue:Severe(N=2545, 843)1.9 (1.4 to 2.5)1.4 (0.7 to 2.5)
Chills:Any(N=2545, 843)16.0 (14.6 to 17.4)10.3 (8.3 to 12.6)
Chills:Mild(N=2545, 843)10.6 (9.4 to 11.9)8.1 (6.3 to 10.1)
Chills:Moderate(N=2545, 843)4.8 (4.0 to 5.7)1.8 (1.0 to 2.9)
Chills:Severe(N=2545, 843)0.6 (0.3 to 1.0)0.5 (0.1 to 1.2)
Muscle pain:Any(N=2545, 843)17.8 (16.3 to 19.3)10.3 (8.3 to 12.6)
Muscle pain:Mild(N=2545, 843)8.7 (7.6 to 9.8)5.2 (3.8 to 6.9)
Muscle pain:Moderate(N=2545, 843)7.9 (6.8 to 9.0)4.5 (3.2 to 6.1)
Muscle pain:Severe(N=2545, 843)1.2 (0.8 to 1.7)0.6 (0.2 to 1.4)
Joint pain:Any(N=2545, 843)16.7 (15.3 to 18.2)9.1 (7.3 to 11.3)
Joint pain:Mild(N=2545, 843)8.4 (7.4 to 9.6)5.0 (3.6 to 6.7)
Joint pain:Moderate(N=2545, 843)7.5 (6.5 to 8.6)3.4 (2.3 to 4.9)
Joint pain:Severe(N=2545, 843)0.8 (0.5 to 1.2)0.7 (0.3 to 1.5)
Antipyretic medication(N=2545, 843)13.6 (12.3 to 15.0)8.9 (7.1 to 11.0)
PrimaryPercentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Third Vaccination

Here, N signifies participants with known values reporting specific characteristic.

Time frame:
Within 7 Days after third vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Third Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Fever >=38 degrees C(N=2414, 819)2.7 (2.1 to 3.4)2.3 (1.4 to 3.6)
Fever 38 to <38.5degreesC(N=2414, 819)1.8 (1.3 to 2.4)1.3 (0.7 to 2.4)
Fever 38.5 to<39 degrees C(N=2414, 819)0.6 (0.3 to 1.0)0.4 (0.1 to 1.1)
Fever 39 to 40 degrees C(N=2414, 819)0.3 (0.1 to 0.6)0.5 (0.1 to 1.2)
Fever >40 degrees C(N=2414, 819)0.0 (0.0 to 0.2)0.1 (0.0 to 0.7)
Vomiting:Any(N=2421, 821)1.7 (1.3 to 2.3)2.2 (1.3 to 3.4)
Vomiting:Mild(N=2421, 821)1.4 (1.0 to 2.0)1.7 (0.9 to 2.8)
Vomiting:Moderate(N=2421, 821)0.3 (0.1 to 0.6)0.5 (0.1 to 1.2)
Vomiting:Severe(N=2421, 821)0.0 (0.0 to 0.2)0.0 (0.0 to 0.4)
Diarrhea:Any(N=2421, 821)7.7 (6.7 to 8.9)7.6 (5.8 to 9.6)
Diarrhea:Mild(N=2421, 821)6.4 (5.5 to 7.5)6.2 (4.7 to 8.1)
Diarrhea:Moderate(N=2421, 821)1.0 (0.6 to 1.5)1.1 (0.5 to 2.1)
Diarrhea:Severe(N=2421, 821)0.3 (0.1 to 0.6)0.2 (0.0 to 0.9)
Headache:Any(N=2421, 821)35.4 (33.5 to 37.4)24.8 (21.9 to 28.0)
Headache:Mild(N=2421, 821)18.9 (17.3 to 20.5)13.5 (11.3 to 16.1)
Headache:Moderate(N=2421, 821)15.2 (13.8 to 16.7)10.4 (8.4 to 12.6)
Headache:Severe(N=2421, 821)1.3 (0.9 to 1.9)1.0 (0.4 to 1.9)
Fatigue:Any(N=2421, 821)35.9 (34.0 to 37.9)24.4 (21.5 to 27.4)
Fatigue:Mild(N=2421, 821)18.4 (16.9 to 20.0)13.5 (11.3 to 16.1)
Fatigue:Moderate(N=2421, 821)15.2 (13.8 to 16.7)10.0 (8.0 to 12.2)
Fatigue:Severe(N=2421, 821)2.3 (1.8 to 3.0)0.9 (0.3 to 1.7)
Chills:Any(N=2421, 821)13.1 (11.7 to 14.5)8.3 (6.5 to 10.4)
Chills:Mild(N=2421, 821)8.7 (7.6 to 9.9)6.5 (4.9 to 8.4)
Chills:Moderate(N=2421, 821)3.8 (3.1 to 4.7)1.7 (0.9 to 2.8)
Chills:Severe(N=2421, 821)0.5 (0.3 to 0.9)0.1 (0.0 to 0.7)
Muscle pain:Any(N=2421, 821)17.6 (16.1 to 19.1)11.1 (9.0 to 13.4)
Muscle pain:Mild(N=2421, 821)9.5 (8.4 to 10.8)6.6 (5.0 to 8.5)
Muscle pain:Moderate(N=2421, 821)7.2 (6.2 to 8.3)4.3 (3.0 to 5.9)
Muscle pain:Severe(N=2421, 821)0.8 (0.5 to 1.3)0.2 (0.0 to 0.9)
Joint pain:Any(N=2421, 821)16.0 (14.6 to 17.5)8.9 (7.0 to 11.1)
Joint pain:Mild(N=2421, 821)8.9 (7.8 to 10.1)5.5 (4.0 to 7.3)
Joint pain:Moderate(N=2421, 821)5.9 (5.0 to 6.9)3.0 (2.0 to 4.5)
Joint pain:Severe(N=2421, 821)1.2 (0.8 to 1.8)0.4 (0.1 to 1.1)
Antipyretic medication(N=2421, 821)12.7 (11.4 to 14.1)6.8 (5.2 to 8.8)
PrimaryPercentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After First Vaccination
Time frame:
Within 30 days after first vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After First Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After First Vaccination0.26 (0.1 to 0.5)0.33 (0.1 to 1.0)
PrimaryPercentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Second Vaccination
Time frame:
Within 30 days after second vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Second Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Second Vaccination0.23 (0.1 to 0.5)0.23 (0.0 to 0.8)
PrimaryPercentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Third Vaccination
Time frame:
Within 30 days after third vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Third Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Third Vaccination0.32 (0.1 to 0.6)0.36 (0.1 to 1.0)
PrimaryPercentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Any Vaccination
Time frame:
Within 30 days after any vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Any Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Any Vaccination0.78 (0.5 to 1.2)0.89 (0.4 to 1.7)
PrimaryPercentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Vaccination Phase
Time frame:
From the first vaccination up to 1 month after the third vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Vaccination Phase
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Vaccination Phase1.49 (1.1 to 2.0)1.90 (1.1 to 3.0)
PrimaryPercentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Follow-Up Phase
Time frame:
From 1 month after third vaccination up to 6 months after the third vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Follow-Up Phase
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Follow-Up Phase0.44 (0.2 to 0.8)0.60 (0.2 to 1.4)
PrimaryPercentage of Participants With at Least 1 Serious Adverse Event (SAE) Throughout the Study Period
Time frame:
From the first vaccination up to 6 month after the third vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Throughout the Study Period
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Throughout the Study Period1.89 (1.4 to 2.5)2.45 (1.5 to 3.7)
PrimaryPercentage of Participants With at Least 1 Medically Attended AE Within 30 Days After First Vaccination
Time frame:
Within 30 days after first vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After First Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After First Vaccination5.27 (4.5 to 6.2)6.69 (5.1 to 8.5)
PrimaryPercentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Second Vaccination
Time frame:
Within 30 days after second vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Second Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Second Vaccination5.91 (5.0 to 6.9)6.51 (5.0 to 8.4)
PrimaryPercentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Third Vaccination
Time frame:
Within 30 days after third vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Third Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Third Vaccination5.81 (4.9 to 6.8)7.43 (5.7 to 9.4)
PrimaryPercentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination
Time frame:
Within 30 days after any vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination14.18 (12.9 to 15.6)16.61 (14.2 to 19.2)
PrimaryPercentage of Participants With at Least 1 Medically Attended AE During the Vaccination Phase
Time frame:
From the first vaccination up to 1 month after the third vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Medically Attended AE During the Vaccination Phase
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Medically Attended AE During the Vaccination Phase25.29 (23.7 to 27.0)27.87 (25.0 to 30.9)
PrimaryPercentage of Participants With at Least 1 Medically Attended AE During the Follow-Up Phase
Time frame:
From 1 month after third vaccination up to 6 months after the third vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Medically Attended AE During the Follow-Up Phase
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Medically Attended AE During the Follow-Up Phase15.61 (14.2 to 17.1)16.92 (14.4 to 19.6)
PrimaryPercentage of Participants With at Least 1 Medically Attended AE Throughout the Study Period
Time frame:
From the first vaccination up to 6 month after the third vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Medically Attended AE Throughout the Study Period
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Medically Attended AE Throughout the Study Period32.38 (30.6 to 34.2)35.56 (32.4 to 38.8)
PrimaryPercentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After First Vaccination
Time frame:
Within 30 days after first vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After First Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After First Vaccination0.00 (0.0 to 0.1)0.11 (0.0 to 0.6)
PrimaryPercentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Second Vaccination
Time frame:
30 days after second vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Second Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Second Vaccination0.08 (0.0 to 0.3)0.12 (0.0 to 0.6)
PrimaryPercentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Third Vaccination
Time frame:
Within 30 days after third vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Third Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Third Vaccination0.12 (0.0 to 0.4)0.00 (0.0 to 0.4)
PrimaryPercentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Any Vaccination
Time frame:
Within 30 Days After any Vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Any Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Any Vaccination0.19 (0.1 to 0.4)0.22 (0.0 to 0.8)
PrimaryPercentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Vaccination Phase
Time frame:
From the first vaccination up to 1 month after the third vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Vaccination Phase
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Vaccination Phase0.37 (0.2 to 0.7)0.56 (0.2 to 1.3)
PrimaryPercentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Follow-Up Phase
Time frame:
From 1 month after third vaccination up to 6 months after the third vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Follow-Up Phase
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Follow-Up Phase0.20 (0.1 to 0.5)0.60 (0.2 to 1.4)
PrimaryPercentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Throughout the Study Period
Time frame:
From the first vaccination up to 6 month after the third vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Throughout the Study Period
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Throughout the Study Period0.56 (0.3 to 0.9)1.11 (0.5 to 2.0)
PrimaryPercentage of Participants With at Least 1 Adverse Event (AE) WIthin 30 Days After First Vaccination
Time frame:
Within 30 days after first vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Adverse Event (AE) WIthin 30 Days After First Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Adverse Event (AE) WIthin 30 Days After First Vaccination9.51 (8.4 to 10.7)10.70 (8.8 to 12.9)
PrimaryPercentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Second Vaccination
Time frame:
Within 30 days after second vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Second Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Second Vaccination11.48 (10.3 to 12.8)12.67 (10.5 to 15.1)
PrimaryPercentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Third Vaccination
Time frame:
Within 30 days after third vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Third Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Third Vaccination9.91 (8.8 to 11.2)10.78 (8.8 to 13.1)
PrimaryPercentage of Participants With at Least 1 Adverse Event Within 30 Days After Any Vaccination
Time frame:
Within 30 Days after any vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Adverse Event Within 30 Days After Any Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Adverse Event Within 30 Days After Any Vaccination25.32 (23.7 to 27.0)26.76 (23.9 to 29.8)
PrimaryPercentage of Participants With at Least 1 Adverse Event During the Vaccination Phase
Time frame:
From the first vaccination up to 1 month after the third vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Adverse Event During the Vaccination Phase
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants With at Least 1 Adverse Event During the Vaccination Phase40.74 (38.9 to 42.6)43.70 (40.4 to 47.0)
PrimaryPercentage of Participants Reporting at Least 1 Immediate AE After First Vaccination
Time frame:
Within 30 minutes after first vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Reporting at Least 1 Immediate AE After First Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants Reporting at Least 1 Immediate AE After First Vaccination0.1 (0.0 to 0.4)0.2 (0.0 to 0.8)
PrimaryPercentage of Participants Reporting at Least 1 Immediate AE After Second Vaccination
Time frame:
Within 30 minutes after second vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Reporting at Least 1 Immediate AE After Second Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants Reporting at Least 1 Immediate AE After Second Vaccination0.2 (0.0 to 0.4)0.1 (0.0 to 0.6)
PrimaryPercentage of Participants Reporting at Least 1 Immediate AE After Third Vaccination
Time frame:
Within 30 minutes after third vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Reporting at Least 1 Immediate AE After Third Vaccination
percentage of participantsrLP2086 (Lots 1-3)Group 4 HAV/Saline
Percentage of Participants Reporting at Least 1 Immediate AE After Third Vaccination0.1 (0.0 to 0.3)0.0 (0.0 to 0.4)
PrimaryNumber of Days Participant's Missed School or Work Due to AE During the Vaccination Phase
Time frame:
From the first vaccination up to 1 month after the third vaccination
Reported as:
Mean · days
Number of Days Participant's Missed School or Work Due to AE During the Vaccination Phase
daysrLP2086 (Lots 1-3)Group 4 HAV/Saline
Number of Days Participant's Missed School or Work Due to AE During the Vaccination Phase3.9 ± 6.564.0 ± 5.19
SecondaryPercentage of Participants With hSBA Titers >=LLOQ for 10 Secondary Strains Before First Vaccination and 1 Month After Third Bivalent rLP2086 Vaccination for Group 1

Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2, 3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.

Time frame:
Before first vaccination, 1 month after third vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With hSBA Titers >=LLOQ for 10 Secondary Strains Before First Vaccination and 1 Month After Third Bivalent rLP2086 Vaccination for Group 1
percentage of participantsGroup 1 rLP2086 Lot 1
PMB3175[A29]:Before Vaccination 1 (N= 269)17.5 (13.1 to 22.5)
PMB3175[A29]:1 Month after Vaccination 3 (N= 278)98.6 (96.4 to 99.6)
PMB3010[A06]:Before Vaccination 1 (N= 277)9.4 (6.2 to 13.5)
PMB3010[A06]:1 Month after Vaccination 3 (N= 280)95.7 (92.6 to 97.8)
PMB3040[A07]:Before Vaccination 1 (N= 269)43.1 (37.1 to 49.3)
PMB3040[A07]:1 Month after Vaccination 3 (N= 280)96.4 (93.5 to 98.3)
PMB824[A12]: Before Vaccination 1 (N= 280)3.9 (2.0 to 6.9)
PMB824[A12]:1 Month after Vaccination 3 (N= 277)75.1 (69.6 to 80.1)
PMB1672[A15]:Before Vaccination 1 (N= 270)20.7 (16.1 to 26.1)
PMB1672[A15]:1 Month after Vaccination 3 (N= 266)87.2 (82.6 to 91.0)
PMB1989[A19]:Before Vaccination 1 (N= 274)11.3 (7.8 to 15.7)
PMB1989[A19]:1 Month after Vaccination 3 (N= 275)92.7 (89.0 to 95.5)
PMB1256[B03]:Before Vaccination 1 (N= 280)4.3 (2.2 to 7.4)
PMB1256[B03]:1 Month after Vaccination 3 (N= 279)92.5 (88.7 to 95.3)
PMB866[B09]:Before Vaccination 1 (N= 277)15.2 (11.2 to 19.9)
PMB866[B09]:1 Month after Vaccination 3 (N= 276)86.2 (81.6 to 90.1)
PMB431[B15]:Before Vaccination 1 (N= 275)28.7 (23.5 to 34.5)
PMB431[B15]:1 Month after Vaccination 3 (N= 281)98.2 (95.9 to 99.4)
PMB648[B16]:Before Vaccination 1 (N= 276)7.6 (4.8 to 11.4)
PMB648[B16]:1 Month after Vaccination 3 (N= 278)81.7 (76.6 to 86.0)
SecondaryPercentage of Participants With hSBA Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, >=1:128 for Each of the 10 Secondary Strains, Before Vaccination 1 and 1 Month After the Third Bivalent rLP2086 Vaccination for Group 1

Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2, 3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.

Time frame:
Before first vaccination, 1 month after third vaccination (Vac)
Reported as:
Number · percentage of participants
Percentage of Participants With hSBA Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, >=1:128 for Each of the 10 Secondary Strains, Before Vaccination 1 and 1 Month After the Third Bivalent rLP2086 Vaccination for Group 1
percentage of participantsGroup 1 rLP2086 Lot 1
Before Vaccination 1: PMB3175[A29] 1:4 (N=269)19.0 (14.5 to 24.2)
1 month after Vac 3: PMB3175[A29] 1:4 (N=278)98.6 (96.4 to 99.6)
Before Vaccination 1: PMB3175[A29] 1:8 (N=269)17.5 (13.1 to 22.5)
1 month after Vac 3: PMB3175[A29] 1:8 (N=278)98.6 (96.4 to 99.6)
Before Vaccination 1: PMB3175[A29] 1:16 (N=269)16.7 (12.5 to 21.7)
1 month after Vac 3: PMB3175[A29] 1:16 (N=278)98.6 (96.4 to 99.6)
Before Vaccination 1: PMB3175[A29] 1:32 (N=269)10.8 (7.3 to 15.1)
1 month after Vac 3: PMB3175[A29] 1:32 (N=278)97.5 (94.9 to 99.0)
Before Vaccination 1: PMB3175[A29] 1:64 (N=269)4.8 (2.6 to 8.1)
1 month after Vac 3: PMB3175[A29] 1:64 (N=278)86.0 (81.3 to 89.8)
Before Vaccination 1: PMB3175[A29] 1:128 (N=269)1.1 (0.2 to 3.2)
1 month after Vac 3: PMB3175[A29] 1:128 (N=278)52.2 (46.1 to 58.2)
Before Vaccination 1: PMB3010[A06] 1:4 (N=277)9.7 (6.5 to 13.9)
1 month after Vac 3: PMB3010[A06] 1:4 (N=280)96.1 (93.1 to 98.0)
Before Vaccination 1: PMB3010[A06] 1:8 (N=277)9.7 (6.5 to 13.9)
1 month after Vac 3: PMB3010[A06] 1:8 (N=280)96.1 (93.1 to 98.0)
Before Vaccination 1: PMB3010[A06] 1:16 (N=277)9.4 (6.2 to 13.5)
1 month after Vac 3: PMB3010[A06] 1:16 (N=280)95.7 (92.6 to 97.8)
Before Vaccination 1: PMB3010[A06] 1:32 (N=277)6.1 (3.6 to 9.6)
1 month after Vac 3: PMB3010 [A06] 1:32 (N=280)93.6 (90.0 to 96.1)
Before Vaccination 1: PMB3010[A06] 1:64 (N=277)2.9 (1.3 to 5.6)
1 month after Vac 3: PMB3010[A06] 1:64 (N=280)78.2 (72.9 to 82.9)
Before Vaccination 1: PMB3010[A06] 1:128 (N=277)1.4 (0.4 to 3.7)
1 month after Vac 3: PMB3010[A06] 1:128 (N=280)44.3 (38.4 to 50.3)
Before Vaccination 1: PMB3040[A07] 1:4 (N=269)43.1 (37.1 to 49.3)
1 month after Vac 3: PMB3040[A07] 1:4 (N=280)96.4 (93.5 to 98.3)
Before Vaccination 1: PMB3040[A07] 1:8 (N=269)43.1 (37.1 to 49.3)
1 month after Vac 3: PMB3040[A07] 1:8 (N=280)96.4 (93.5 to 98.3)
Before Vaccination 1: PMB3040[A07] 1:16 (N=269)42.8 (36.8 to 48.9)
1 month after Vac 3: PMB3040[A07] 1:16 (N=280)96.4 (93.5 to 98.3)
Before Vaccination 1: PMB3040[A07] 1:32 (N=269)37.2 (31.4 to 43.3)
1 month after Vac 3: PMB3040[A07] 1:32 (N=280)93.6 (90.0 to 96.1)
Before Vaccination 1: PMB3040[A07] 1:64 (N=269)21.6 (16.8 to 27.0)
1 month after Vac 3: PMB3040[A07] 1:64 (N=280)78.2 (72.9 to 82.9)
Before Vaccination 1: PMB3040[A07] 1:128 (N=269)5.6 (3.2 to 9.0)
1 month after Vac 3: PMB3040[A07] 1:128 (N=280)30.4 (25.0 to 36.1)
Before Vaccination 1: PMB824[A12] 1:4 (N=280)5.4 (3.0 to 8.7)
1 month after Vac 3: PMB824[A12] 1:4 (N=277)77.6 (72.2 to 82.4)
Before Vaccination 1: PMB824[A12] 1:8 (N=280)4.6 (2.5 to 7.8)
1 month after Vac 3: PMB824[A12] 1:8 (N=277)77.3 (71.9 to 82.1)
Before Vaccination 1: PMB824[A12] 1:16 (N=280)3.9 (2.0 to 6.9)
1 month after Vac 3: PMB824[A12] 1:16 (N=277)75.1 (69.6 to 80.1)
Before Vaccination 1: PMB824[A12] 1:32 (N=280)2.5 (1.0 to 5.1)
1 month after Vac 3: PMB824[A12] 1:32 (N=277)51.3 (45.2 to 57.3)
Before Vaccination 1: PMB824[A12] 1:64 (N=280)0.0 (0.0 to 1.3)
1 month after Vac 3: PMB824[A12] 1:64 (N=277)19.5 (15.0 to 24.7)
Before Vaccination 1: PMB824[A12] 1:128 (N=280)0.0 (0.0 to 1.3)
1 month after Vac 3: PMB824[A12] 1:128 (N=277)1.8 (0.6 to 4.2)
Before Vaccination 1: PMB1672[A15] 1:4 (N=270)22.6 (17.7 to 28.1)
1 month after Vac 3: PMB1672[A15] 1:4 (N=266)87.2 (82.6 to 91.0)
Before Vaccination 1: PMB1672[A15] 1:8 (N=270)20.7 (16.1 to 26.1)
1 month after Vac 3: PMB1672[A15] 1:8 (N=266)87.2 (82.6 to 91.0)
Before Vaccination 1: PMB1672[A15] 1:16 (N=270)17.0 (12.8 to 22.1)
1 month after Vac 3: PMB1672[A15] 1:16 (N=266)85.0 (80.1 to 89.0)
Before Vaccination 1: PMB1672[A15] 1:32 (N=270)13.3 (9.5 to 18.0)
1 month after Vac 3: PMB1672[A15] 1:32 (N=266)71.4 (65.6 to 76.8)
Before Vaccination 1: PMB1672[A15] 1:64 (N=270)3.7 (1.8 to 6.7)
1 month after Vac 3: PMB1672[A15] 1:64 (N=266)40.2 (34.3 to 46.4)
Before Vaccination 1: PMB1672[A15] 1:128 (N=270)0.4 (0.0 to 2.0)
1 month after Vac 3: PMB1672[A15] 1:128 (N=266)10.5 (7.1 to 14.9)
Before Vaccination 1: PMB1989[A19] 1:4 (N=274)20.8 (16.2 to 26.1)
1 month after Vac 3: PMB1989[A19] 1:4 (N=275)93.8 (90.3 to 96.4)
Before Vaccination 1: PMB1989[A19] 1:8 (N=274)18.6 (14.2 to 23.7)
1 month after Vac 3: PMB1989[A19] 1:8 (N=275)93.8 (90.3 to 96.4)
Before Vaccination 1: PMB1989[A19] 1:16 (N=274)11.3 (7.8 to 15.7)
1 month after Vac 3: PMB1989[A19] 1:16 (N=275)92.7 (89.0 to 95.5)
Before Vaccination 1: PMB1989[A19] 1:32 (N=274)5.8 (3.4 to 9.3)
1 month after Vac 3: PMB1989[A19] 1:32 (N=275)85.5 (80.7 to 89.4)
Before Vaccination 1: PMB1989[A19] 1:64 (N=274)1.8 (0.6 to 4.2)
1 month after Vac 3: PMB1989[A19] 1:64 (N=275)60.0 (53.9 to 65.8)
Before Vaccination 1: PMB1989[A19] 1:128 (N=274)0.4 (0.0 to 2.0)
1 month after Vac 3: PMB1989[A19] 1:128 (N=275)33.1 (27.6 to 39.0)
Before Vaccination 1: PMB1256[B03] 1:4 (N=280)5.0 (2.8 to 8.2)
1 month after Vac 3: PMB1256[B03] 1:4 (N=279)92.5 (88.7 to 95.3)
Before Vaccination 1: PMB1256[B03] 1:8 (N=280)4.3 (2.2 to 7.4)
1 month after Vac 3: PMB1256[B03] 1:8 (N=279)92.5 (88.7 to 95.3)
Before Vaccination 1: PMB1256[B03] 1:16 (N=280)4.3 (2.2 to 7.4)
1 month after Vac 3: PMB1256[B03] 1:16 (N=279)92.1 (88.3 to 95.0)
Before Vaccination 1: PMB1256[B03] 1:32 (N=280)3.9 (2.0 to 6.9)
1 month after Vac 3: PMB1256[B03] 1:32 (N=279)81.4 (76.3 to 85.8)
Before Vaccination 1: PMB1256[B03] 1:64 (N=280)2.9 (1.2 to 5.6)
1 month after Vac 3: PMB1256[B03] 1:64 (N=279)60.6 (54.6 to 66.3)
Before Vaccination 1: PMB1256[B03] 1:128 (N=280)0.4 (0.0 to 2.0)
1 month after Vac 3: PMB1256[B03] 1:128 (N=279)29.4 (24.1 to 35.1)
Before Vaccination 1: PMB866[B09] 1:4 (N=277)15.5 (11.5 to 20.3)
1 month after Vac 3: PMB866[B09] 1:4 (N=276)86.6 (82.0 to 90.4)
Before Vaccination 1: PMB866[B09] 1:8 (N=277)15.2 (11.2 to 19.9)
1 month after Vac 3: PMB866[B09] 1:8 (N=276)86.2 (81.6 to 90.1)
Before Vaccination 1: PMB866[B09] 1:16 (N=277)13.7 (9.9 to 18.3)
1 month after Vac 3: PMB866[B09] 1:16 (N=276)83.7 (78.8 to 87.9)
Before Vaccination 1: PMB866[B09] 1:32 (N=277)8.7 (5.6 to 12.6)
1 month after Vac 3: PMB866[B09] 1:32 (N=276)54.0 (47.9 to 60.0)
Before Vaccination 1: PMB866[B09] 1:64 (N=277)0.4 (0.0 to 2.0)
1 month after Vac 3: PMB866[B09] 1:64 (N=276)21.4 (16.7 to 26.7)
Before Vaccination 1: PMB866[B09] 1:128 (N=277)0.0 (0.0 to 1.3)
1 month after Vac 3: PMB866[B09] 1:128 (N=276)4.3 (2.3 to 7.5)
Before Vaccination 1: PMB431[B15] 1:4 (N=275)30.5 (25.2 to 36.4)
1 month after Vac 3: PMB431[B15] 1:4 (N=281)98.2 (95.9 to 99.4)
Before Vaccination 1: PMB431[B15] 1:8 (N=275)28.7 (23.5 to 34.5)
1 month after Vac 3: PMB431[B15] 1:8 (N=281)98.2 (95.9 to 99.4)
Before Vaccination 1: PMB431[B15] 1:16 (N=275)27.6 (22.4 to 33.3)
1 month after Vac 3: PMB431[B15] 1:16 (N=281)97.5 (94.9 to 99.0)
Before Vaccination 1: PMB431[B15] 1:32 (N=275)21.8 (17.1 to 27.2)
1 month after Vac 3: PMB431[B15] 1:32 (N=281)85.1 (80.3 to 89.0)
Before Vaccination 1: PMB431[B15] 1:64 (N=275)8.4 (5.4 to 12.3)
1 month after Vac 3: PMB431[B15] 1:64 (N=281)56.2 (50.2 to 62.1)
Before Vaccination 1: PMB431[B15] 1:128 (N=275)0.4 (0.0 to 2.0)
1 month after Vac 3: PMB431[B15] 1:128 (N=281)19.2 (14.8 to 24.3)
Before Vaccination 1: PMB648[B16] 1:4 (N=276)8.7 (5.7 to 12.7)
1 month after Vac 3: PMB648[B16] 1:4 (N=278)82.7 (77.8 to 87.0)
Before Vaccination 1: PMB648[B16] 1:8 (N=276)7.6 (4.8 to 11.4)
1 month after Vac 3: PMB648[B16] 1:8 (N=278)81.7 (76.6 to 86.0)
Before Vaccination 1: PMB648[B16] 1:16 (N=276)7.6 (4.8 to 11.4)
1 month after Vac 3: PMB648[B16] 1:16 (N=278)79.9 (74.7 to 84.4)
Before Vaccination 1: PMB648[B16] 1:32 (N=276)6.2 (3.6 to 9.7)
1 month after Vac 3: PMB648[B16] 1:32 (N=278)54.0 (47.9 to 59.9)
Before Vaccination 1: PMB648[B16] 1:64 (N=276)1.8 (0.6 to 4.2)
1 month after Vac 3: PMB648[B16] 1:64 (N=278)24.1 (19.2 to 29.6)
Before Vaccination 1: PMB648[B16] 1:128 (N=276)0.4 (0.0 to 2.0)
1 month after Vac 3: PMB648[B16] 1:128 (N=278)5.8 (3.3 to 9.2)
SecondaryhSBA Geometric Mean Titers (GMTs) for Each of the 10 Secondary Strains Before First Vaccination and 1 Month After the Third Bivalent rLP2086 Vaccination for Group 1

Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2, 3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.

Time frame:
Before first vaccination, 1 month after third vaccination
Reported as:
Geometric mean · titer
hSBA Geometric Mean Titers (GMTs) for Each of the 10 Secondary Strains Before First Vaccination and 1 Month After the Third Bivalent rLP2086 Vaccination for Group 1
titerGroup 1 rLP2086 Lot 1
PMB3175[A29]:Before Vaccination 1 (N= 269)5.7 (5.16 to 6.28)
PMB3175[A29]:1 Month after Vaccination 3 (N= 278)93.5 (84.79 to 103.09)
PMB3010[A06]:Before Vaccination 1 (N= 277)9.3 (8.68 to 9.91)
PMB3010[A06]:1 Month after Vaccination 3 (N= 280)78.6 (70.94 to 87.08)
PMB3040[A07]:Before Vaccination 1 (N= 269)11.4 (9.75 to 13.23)
PMB3040[A07]:1 Month after Vaccination 3 (N= 280)63.5 (57.93 to 69.66)
PMB824[A12]: Before Vaccination 1 (N= 280)8.4 (8.14 to 8.59)
PMB824[A12]:1 Month after Vaccination 3 (N= 277)22.3 (20.37 to 24.45)
PMB1672[A15]:Before Vaccination 1 (N= 270)5.9 (5.32 to 6.46)
PMB1672[A15]:1 Month after Vaccination 3 (N= 266)31.0 (27.43 to 35.07)
PMB1989[A19]:Before Vaccination 1 (N= 274)9.1 (8.70 to 9.62)
PMB1989[A19]:1 Month after Vaccination 3 (N= 275)57.6 (51.30 to 64.60)
PMB1256[B03]:Before Vaccination 1 (N= 280)4.5 (4.19 to 4.75)
PMB1256[B03]:1 Month after Vaccination 3 (N= 279)51.7 (45.36 to 58.89)
PMB866[B09]:Before Vaccination 1 (N= 277)5.2 (4.82 to 5.62)
PMB866[B09]:1 Month after Vaccination 3 (N= 276)22.9 (20.48 to 25.63)
PMB431[B15]:Before Vaccination 1 (N= 275)7.3 (6.49 to 8.23)
PMB431[B15]:1 Month after Vaccination 3 (N= 281)47.7 (43.66 to 52.16)
PMB648[B16]:Before Vaccination 1 (N= 276)4.7 (4.39 to 5.05)
PMB648[B16]:1 Month after Vaccination 3 (N= 278)22.1 (19.60 to 24.98)
SecondaryPercentage of Participants Achieving Composite hSBA Titer >=Lower Limit of Quantitation for All 4 Primary Strains Before First Vaccination and 1 Month After Second Bivalent rLP2086 Vaccination for Group 1

Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2 ,3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.

Time frame:
Before vaccination 1, 1 Month after Vaccination 2
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Composite hSBA Titer >=Lower Limit of Quantitation for All 4 Primary Strains Before First Vaccination and 1 Month After Second Bivalent rLP2086 Vaccination for Group 1
percentage of participantsGroup 1 rLP2086 Lot 1
Before First Vaccination (N= 1088)1.1 (0.6 to 1.9)
1 Month after Vaccination 2 (N= 1122)54.1 (51.1 to 57.0)
SecondaryPercentage of Participants Achieving at Least a 4-Fold Increase in hSBA Titer for Each of the 4 Primary Strains Before First Vaccination to 1 Month After the Second Bivalent rLP2086 Vaccination for Group 1

Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2, 3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.

Time frame:
One month after second Bivalent rLP2086 vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least a 4-Fold Increase in hSBA Titer for Each of the 4 Primary Strains Before First Vaccination to 1 Month After the Second Bivalent rLP2086 Vaccination for Group 1
percentage of participantsGroup 1 rLP2086 Lot 1
PMB80[A22] (N=1223)73.8 (71.2 to 76.2)
PMB2001[A56] (N=1122)84.8 (82.5 to 86.8)
PMB2948[B24] (N=1201)56.2 (53.3 to 59.0)
PMB2707[B44] (N=1197)55.9 (53.0 to 58.7)
SecondaryPercentage of Participants Achieving at Least a 4-Fold Increase in hSBA Titer for 2 Primary Strains Before First Vaccination to 1 Month After the Second and Third Bivalent rLP2086 Vaccination
Time frame:
One month after second, third vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least a 4-Fold Increase in hSBA Titer for 2 Primary Strains Before First Vaccination to 1 Month After the Second and Third Bivalent rLP2086 Vaccination
percentage of participantsGroup 2 rLP2086 Lot 2Group 3 rLP2086 Lot 3
PMB80[A22]:1Month after Vaccination 2 (N=493, 473)71.2 (67.0 to 75.2)74.6 (70.5 to 78.5)
PMB80[A22]:1Month after Vaccination 3 (N=501, 478)83.8 (80.3 to 86.9)86.0 (82.5 to 89.0)
PMB2948[B24]:1Month after Vaccination 2(N=490,463)56.7 (52.2 to 61.2)56.8 (52.2 to 61.4)
PMB2948[B24]:1Month after Vaccination 3(N=507,472)76.5 (72.6 to 80.2)78.4 (74.4 to 82.0)
SecondaryhSBA Geometric Mean Titers (GMTs) for 4 Primary Test Strains and for 2 Primary Test Strains and Before First Vaccination and 1 Month After the Second Bivalent rLP2086 Vaccination
Time frame:
Before vaccination (Vac) 1, 1 Month after Vac 2
Reported as:
Geometric mean · titer
hSBA Geometric Mean Titers (GMTs) for 4 Primary Test Strains and for 2 Primary Test Strains and Before First Vaccination and 1 Month After the Second Bivalent rLP2086 Vaccination
titerGroup 1 rLP2086 Lot 1Group 2 rLP2086 Lot 2Group 3 rLP2086 Lot 3
PMB80[A22]: Before Vac 1 (N=1238, 502, 479)12.6 (12.08 to 13.14)12.9 (12.06 to 13.79)12.2 (11.43 to 13.04)
PMB80[A22]: 1 Month after Vac 2 (N=1263, 510, 487)50.4 (47.76 to 53.09)47.7 (43.82 to 51.97)49.6 (45.58 to 53.99)
PMB2001[A56]: Before Vac 1 (N=1135, 0, 0)8.4 (7.80 to 9.05)NA (NA to NA)NA (NA to NA)
PMB2001[A56]: 1 Month after Vac 2 (N=1222, 0, 0)131.2 (124.03 to 138.70)NA (NA to NA)NA (NA to NA)
PMB2948[B24]: Before Vac 1 (N=1264, 510, 486)4.5 (4.37 to 4.60)4.6 (4.43 to 4.85)4.6 (4.43 to 4.88)
PMB2948[B24]: 1 Month after Vac 2 (N=1216,499,470)14.3 (13.45 to 15.31)14.5 (13.23 to 15.98)15.2 (13.75 to 16.85)
PMB2707[B44]: Before Vac 1 (N=1230, 0, 0)4.3 (4.17 to 4.34)NA (NA to NA)NA (NA to NA)
PMB2707[B44]: 1 Month after Vac 2 (N=1204, 0, 0)17.1 (15.80 to 18.60)NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants With hSBA Titers >=LLOQ for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination
Time frame:
Before Vaccination (Vac) 1, 1 Month after Vac 2, 3
Reported as:
Number · percentage of participants
Percentage of Participants With hSBA Titers >=LLOQ for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination
percentage of participantsGroup 1 rLP2086 Lot 1Group 2 rLP2086 Lot 2Group 3 rLP2086 Lot 3
Before Vac 1: PMB80[A22] 1:16(N=1238, 502, 479)33.2 (30.6 to 35.9)34.9 (30.7 to 39.2)31.7 (27.6 to 36.1)
1 month afterVac2:PMB80[A22]1:16(N=1263,510,487)94.3 (92.9 to 95.5)92.7 (90.1 to 94.8)94.7 (92.3 to 96.5)
1 month after Vac3:PMB80[A22]1:16(N=1266, 518,492)97.8 (96.8 to 98.5)97.3 (95.5 to 98.5)98.2 (96.6 to 99.2)
Before Vac 1: PMB2001[A56] 1:8(N=1135, 0, 0)27.5 (24.9 to 30.2)NA (NA to NA)NA (NA to NA)
1 month after Vac2:PMB2001[A56]1:8(N=1222, 0, 0)99.1 (98.4 to 99.5)NA (NA to NA)NA (NA to NA)
1 month after Vac3:PMB2001[A56]1:8(N=1229, 0, 0)99.5 (98.9 to 99.8)NA (NA to NA)NA (NA to NA)
Before Vac 1: PMB2948[B24]1:8(N=1264, 510, 486)6.4 (5.1 to 7.9)8.6 (6.3 to 11.4)8.4 (6.1 to 11.3)
1 monthafterVac2:PMB2948[B24]1:8(N=1216,499,470)66.4 (63.6 to 69.0)70.1 (65.9 to 74.1)70.2 (65.9 to 74.3)
1 monthafterVac3:PMB2948[B24]1:8(N=1250,516,479)87.1 (85.1 to 88.9)87.6 (84.4 to 90.3)90.0 (86.9 to 92.5)
Before Vac 1: PMB2707[B44] 1:8(N=1230, 0, 0)3.6 (2.6 to 4.8)NA (NA to NA)NA (NA to NA)
1 month after Vac2:PMB2707[B44]1:8(N=1204, 0, 0)64.0 (61.3 to 66.8)NA (NA to NA)NA (NA to NA)
1 month after Vac3:PMB2707[B44]1:8(N=1210, 0, 0)89.3 (87.4 to 90.9)NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants With hSBA Titers >=1:4,>=1:8,>=1:16,>=1:32,>=1:64,>=1:128 for Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination

Results for PMB80\[A22\] 1:16, PMB2001\[A56\] 1:8, PMB2948\[B24\] 1:8 and PMB2707\[B44\] 1:8 are reported under secondary outcome measure 'Percentage of Participants With hSBA Titers \>=LLOQ for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination.

Time frame:
Before Vaccination (Vac) 1, 1 Month after Vac 2, 3
Reported as:
Number · percentage of participants
Percentage of Participants With hSBA Titers >=1:4,>=1:8,>=1:16,>=1:32,>=1:64,>=1:128 for Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination
percentage of participantsGroup 1 rLP2086 Lot 1Group 2 rLP2086 Lot 2Group 3 rLP2086 Lot 3
Before Vac 1:PMB80[A22] 1:4(N=1238, 502, 479)36.2 (33.5 to 38.9)39.6 (35.3 to 44.1)36.7 (32.4 to 41.2)
1 month after Vac2:PMB80[A22]1:4(N=1263, 510, 487)94.9 (93.6 to 96.1)93.7 (91.3 to 95.7)95.5 (93.2 to 97.1)
1 month after Vac3:PMB80[A22]1:4(N=1266, 518, 492)97.9 (97.0 to 98.7)98.1 (96.5 to 99.1)98.4 (96.8 to 99.3)
Before Vac 1: PMB80[A22] 1:8(N=1238, 502, 479)34.8 (32.2 to 37.5)39.0 (34.8 to 43.5)34.7 (30.4 to 39.1)
1 month after Vac2:PMB80[A22]1:8(N=1263, 510, 487)94.7 (93.3 to 95.9)93.5 (91.0 to 95.5)95.5 (93.2 to 97.1)
1 month after Vac3:PMB80[A22]1:8(N=1266, 518, 492)97.9 (97.0 to 98.7)98.1 (96.5 to 99.1)98.4 (96.8 to 99.3)
Before Vac 1: PMB80[A22] 1:32(N=1238, 502, 479)20.9 (18.7 to 23.3)21.7 (18.2 to 25.6)19.8 (16.4 to 23.7)
1 month after Vac2:PMB80[A22]1:32(N=1263, 510,487)81.9 (79.7 to 84.0)79.4 (75.6 to 82.8)80.7 (76.9 to 84.1)
1 month after Vac3:PMB80[A22]1:32(N=1266,518,492)93.0 (91.4 to 94.3)92.1 (89.4 to 94.3)93.1 (90.5 to 95.2)
Before Vac 1: PMB80[A22] 1:64(N=1238, 502, 479)8.5 (7.0 to 10.2)9.6 (7.1 to 12.5)5.4 (3.6 to 7.9)
1 month after Vac2:PMB80[A22]1:64(N=1263,510,487)51.8 (49.0 to 54.6)49.6 (45.2 to 54.0)51.5 (47.0 to 56.1)
1 month after Vac3:PMB80[A22]1:64(N=1266,518,492)75.3 (72.8 to 77.6)75.5 (71.5 to 79.1)73.6 (69.4 to 77.4)
Before Vac 1: PMB80[A22] 1:128(N=1238, 502,479)2.0 (1.3 to 3.0)2.0 (1.0 to 3.6)2.5 (1.3 to 4.3)
1 month after Vac2:PMB80[A22]1:128(N=1263,510,487)24.5 (22.1 to 26.9)23.5 (19.9 to 27.5)24.4 (20.7 to 28.5)
1 month after Vac3:PMB80[A22]1:128(N=1266,518,492)48.3 (45.6 to 51.1)46.3 (42.0 to 50.7)49.2 (44.7 to 53.7)
Before Vac 1: PMB2001[A56] 1:4(N=1135, 0, 0)29.5 (26.9 to 32.3)NA (NA to NA)NA (NA to NA)
1 month after Vac2:PMB2001[A56]1:4(N=1222, 0, 0)99.1 (98.4 to 99.5)NA (NA to NA)NA (NA to NA)
1 month after Vac3:PMB2001[A56]1:4(N=1229, 0, 0)99.5 (98.9 to 99.8)NA (NA to NA)NA (NA to NA)
Before Vac 1: PMB2001[A56] 1:16(N=1135, 0, 0)27.4 (24.8 to 30.1)NA (NA to NA)NA (NA to NA)
1 month after Vac2:PMB2001[A56]1:16(N=1222,0,0)99.1 (98.4 to 99.5)NA (NA to NA)NA (NA to NA)
1 month after Vac3:PMB2001[A56]1:16(N=1229,0,0)99.4 (98.8 to 99.8)NA (NA to NA)NA (NA to NA)
Before Vac 1: PMB2001[A56] ] 1:32(N=1135, 0, 0)25.6 (23.0 to 28.2)NA (NA to NA)NA (NA to NA)
1 month after Vac2:PMB2001[A56] 1:32(N=1222,0,0)97.2 (96.1 to 98.1)NA (NA to NA)NA (NA to NA)
1 month after Vac3:PMB2001[A56]1:32(N=1229,0,0)98.6 (97.8 to 99.2)NA (NA to NA)NA (NA to NA)
Before Vac 1: PMB2001[A56] 1:64(N=1135, 0, 0)17.1 (14.9 to 19.4)NA (NA to NA)NA (NA to NA)
1 month afterVac2:PMB2001[A56]1:64(N=1222,0,0)89.4 (87.6 to 91.1)NA (NA to NA)NA (NA to NA)
1 month after Vac3:PMB2001[A56]1:64(N=1229,0,0)94.5 (93.0 to 95.7)NA (NA to NA)NA (NA to NA)
Before Vac 1: PMB2001[A56] 1:128(N=1135, 0, 0)6.4 (5.1 to 8.0)NA (NA to NA)NA (NA to NA)
1 month after Vac2:PMB2001[A56]1:128(N=1222,0,0)63.4 (60.6 to 66.1)NA (NA to NA)NA (NA to NA)
1 month afterVac3:PMB2001[A56]1:128(N=1229,0,0)82.9 (80.7 to 85.0)NA (NA to NA)NA (NA to NA)
Before Vac 1: PMB2948[B24] 1:4(N=1264, 510, 486)6.8 (5.5 to 8.3)10.2 (7.7 to 13.2)9.5 (7.0 to 12.4)
1 month after Vac2:PMB2948[B24]1:4(N=1216,499,470)69.2 (66.6 to 71.8)72.9 (68.8 to 76.8)74.0 (69.8 to 78.0)
1 month after Vac3:PMB2948[B24]1:4(N=1250,516,479)88.9 (87.0 to 90.6)89.9 (87.0 to 92.4)91.6 (88.8 to 94.0)
Before Vac 1: PMB2948[B24] 1:16(N=1264, 510, 486)5.4 (4.2 to 6.8)7.5 (5.3 to 10.1)7.0 (4.9 to 9.6)
1 month afterVac2:PMB2948[B24]1:16(N=1216,499,470)60.0 (57.2 to 62.8)61.5 (57.1 to 65.8)62.1 (57.6 to 66.5)
1 month afterVac3:PMB2948[B24]1:16(N=1250,516,479)82.6 (80.4 to 84.7)81.2 (77.6 to 84.5)83.1 (79.4 to 86.3)
Before Vac 1: PMB2948[B24] 1:32(N=1264, 510, 486)2.8 (2.0 to 3.9)3.9 (2.4 to 6.0)3.7 (2.2 to 5.8)
1 month afterVac2:PMB2948[B24]1:32(N=1216,499,470)33.0 (30.3 to 35.7)34.5 (30.3 to 38.8)35.5 (31.2 to 40.0)
1 month afterVac3:PMB2948[B24]1:32(N=1250,516,479)52.1 (49.3 to 54.9)54.8 (50.4 to 59.2)54.1 (49.5 to 58.6)
Before Vac 1:PMB2948[B24] 1:64(N=1264, 510, 486)1.3 (0.7 to 2.0)1.2 (0.4 to 2.5)1.9 (0.9 to 3.5)
1 monthafterVac2:PMB2948[B24]1:64(N=1216,499,470)15.3 (13.3 to 17.4)13.0 (10.2 to 16.3)15.3 (12.2 to 18.9)
1 month afterVac3:PMB2948[B24]1:64(N=1250,516,479)22.8 (20.5 to 25.2)27.5 (23.7 to 31.6)25.3 (21.4 to 29.4)
Before Vac 1:PMB2948[B24] 1:128(N=1264, 510,486)0.5 (0.2 to 1.0)0.2 (0.0 to 1.1)0.4 (0.0 to 1.5)
1 monthafterVac2:PMB2948[B24]1:128(N=1216,499,470)6.2 (4.9 to 7.7)5.2 (3.4 to 7.5)7.0 (4.9 to 9.7)
1 monthafterVac3:PMB2948[B24]1:128(N=1250,516,479)8.9 (7.4 to 10.6)11.2 (8.6 to 14.3)8.6 (6.2 to 11.4)
Before Vac 1: PMB2707[B44] 1:4(N=1230, 0, 0)4.6 (3.5 to 5.9)NA (NA to NA)NA (NA to NA)
1 month after Vac2:PMB2707[B44]1:4(N=1204, 0,0)66.7 (64.0 to 69.4)NA (NA to NA)NA (NA to NA)
1 month after Vac3:PMB2707[B44]1:4(N=1210, 0,0)90.4 (88.6 to 92.0)NA (NA to NA)NA (NA to NA)
Before Vac 1: PMB2707[B44] 1:16(N=1230, 0, 0)3.0 (2.1 to 4.1)NA (NA to NA)NA (NA to NA)
1 month after Vac2:PMB2707[B44]1:16(N=1204,0,0)57.7 (54.9 to 60.5)NA (NA to NA)NA (NA to NA)
1 month afterVac3:PMB2707[B44]1:16(N=1210,0, 0)86.8 (84.7 to 88.6)NA (NA to NA)NA (NA to NA)
Before Vac 1: PMB2707[B44] 1:32(N=1230, 0, 0)1.6 (1.0 to 2.5)NA (NA to NA)NA (NA to NA)
1 month after Vac2:PMB2707[B44]1:32(N=1204,0,0)39.0 (36.3 to 41.9)NA (NA to NA)NA (NA to NA)
1 month after Vac3:PMB2707[B44]1:32(N=1210,0,0)71.6 (68.9 to 74.1)NA (NA to NA)NA (NA to NA)
Before Vac 1:PMB2707[B44] 1:64(N=1230, 0, 0)0.7 (0.3 to 1.3)NA (NA to NA)NA (NA to NA)
1 month after Vac2:PMB2707[B44]1:64(N=1204,0,0)23.3 (21.0 to 25.8)NA (NA to NA)NA (NA to NA)
1 month after Vac3:PMB2707[B44]1:64(N=1210,0,0)54.5 (51.7 to 57.4)NA (NA to NA)NA (NA to NA)
Before Vac 1:PMB2707[B44] 1:128(N=1230, 0, 0)0.2 (0.0 to 0.6)NA (NA to NA)NA (NA to NA)
1 month after Vac2:PMB2707[B44]1:128(N=1204,0,0)13.0 (11.2 to 15.1)NA (NA to NA)NA (NA to NA)
1 month after Vac3:PMB2707[B44]1:128(N=1210,0,0)35.0 (32.4 to 37.8)NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants Achieving at Least a 3-Fold Increase in hSBA Titer for 4 Primary Test Strains and for Primary Test Starins Before First Vaccination to 1 Month After Third Bivalent rLP2086 Vaccination
Time frame:
One month after third bivalent rLP2086 vaccination

No measurements were reported for this outcome.

SecondaryPercentage of Participants Achieving at Least a 2-Fold Increase in hSBA Titer for 4 Primary Test Strains and for 2 Primary Test Starins Before First Vaccination to 1 Month After the Third Bivalent rLP2086 Vaccination
Time frame:
One month after third bivalent rLP2086 vaccination (Vac)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least a 2-Fold Increase in hSBA Titer for 4 Primary Test Strains and for 2 Primary Test Starins Before First Vaccination to 1 Month After the Third Bivalent rLP2086 Vaccination
percentage of participantsGroup 1 rLP2086 Lot 1Group 2 rLP2086 Lot 2Group 3 rLP2086 Lot 3
PMB80[A22]: 1 Month after Vac 3(N=1225, 501, 478)91.43 (89.7 to 92.9)92.02 (89.3 to 94.2)93.51 (90.9 to 95.6)
PMB2001[A56]: 1 Month after Vac 3(N=1128, 0, 0)95.04 (93.6 to 96.2)NA (NA to NA)NA (NA to NA)
PMB2948[B24]: 1 Month after Vac 3(N=1235, 507,472)81.05 (78.8 to 83.2)79.09 (75.3 to 82.6)80.93 (77.1 to 84.4)
PMB2707[B44]: 1 Month after Vac 3(N=1203, 0, 0)86.62 (84.6 to 88.5)NA (NA to NA)NA (NA to NA)

Adverse events

Collected over AEs/SAEs: recorded from first vaccination through 6 months after third vaccination. Participants recorded pre-specified reactogenicity events (local reactions, systemic events) in electronic diary within 7 days after first, second and third vaccination. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1 rLP2086 Lot 1—22/1,508 (1.5%)1,410/1,508 (93.5%)
Group 2 rLP2086 Lot 2—10/598 (1.7%)547/598 (91.5%)
Group 3 rLP2086 Lot 3—19/587 (3.2%)542/587 (92.3%)
Group 4 HAV/Saline—22/897 (2.5%)655/897 (73%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventGroup 1 rLP2086 Lot 1Group 2 rLP2086 Lot 2Group 3 rLP2086 Lot 3Group 4 HAV/Saline
AppendicitisInfections and infestations0/15080/5980/5874/897
CellulitisInfections and infestations0/15080/5980/5872/897
Suicidal ideationPsychiatric disorders1/15080/5981/5872/897
Abdominal painGastrointestinal disorders2/15080/5981/5870/897
NauseaGastrointestinal disorders0/15080/5981/5870/897
PancreatitisGastrointestinal disorders0/15080/5981/5870/897
Appendicitis perforatedInfections and infestations1/15080/5981/5870/897
AbscessInfections and infestations0/15080/5981/5870/897
InfluenzaInfections and infestations0/15080/5981/5870/897
Forearm fractureInjury, poisoning and procedural complications2/15080/5981/5870/897
Most frequent other events
Showing 10 of 47
Most frequent other events
EventGroup 1 rLP2086 Lot 1Group 2 rLP2086 Lot 2Group 3 rLP2086 Lot 3Group 4 HAV/Saline
Pain at injection site -Any (reactogenicity event)Skin and subcutaneous tissue disorders1403/1504544/597541/585525/897
Headache -Any (reactogenicity event)General disorders1032/1504379/597392/585477/893
Fatigue -Any (reactogenicity event)General disorders1011/1504380/597369/585454/893
Muscle pain -Any (reactogenicity event)General disorders598/1504205/597210/585254/893
Chills-Any (reactogenicity event)General disorders566/1504183/597225/585227/893
Joint pain -Any (reactogenicity event)General disorders532/1504170/597191/585209/893
Swelling -Any (reactogenicity event)Skin and subcutaneous tissue disorders416/1504161/597158/58526/893
Redness -Any (reactogenicity event)Skin and subcutaneous tissue disorders365/1504136/597145/58521/893
Diarrhea-Any (reactogenicity event)General disorders294/1504114/597117/585187/893
Fever >=38.0 degrees C -Any (reactogenicity event)General disorders154/150452/59757/58546/892

Baseline characteristics

Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.

Age, Continuous
Age, Continuous(Years)Group 1 rLP2086 Lot 1Group 2 rLP2086 Lot 2Group 3 rLP2086 Lot 3Group 4 HAV/SalineTotal
Mean13.9 ± 2.614.0 ± 2.613.9 ± 2.613.9 ± 2.613.9 ± 2.6
Sex: Female, Male
Sex: Female, Male(Participants)Group 1 rLP2086 Lot 1Group 2 rLP2086 Lot 2Group 3 rLP2086 Lot 3Group 4 HAV/SalineTotal
Female7372862744431740
Male7713123134541850
08

Study locations

99 sites
  • Birmingham Pediatric Associates, PC
    Birmingham, Alabama 35205, United States
  • Alabama Clinical Therapeutics, LLC
    Birmingham, Alabama 35235, United States
  • Southeastern Pediatrics
    Dothan, Alabama 36305, United States
  • Harrisburg Family Medical Center
    Harrisburg, Arkansas 72432, United States
  • The Children's Clinic of Jonesboro, P.A.
    Jonesboro, Arkansas 72401, United States
  • Arkansas Pediatric Clinic
    Little Rock, Arkansas 72205, United States
  • California Research Foundation
    San Diego, California 92103-6204, United States
  • Colorado Springs Health Partners/Clinical Research Advantage, Inc.
    Colorado Springs, Colorado 80922, United States
  • Aga Clinical Trials
    Hialeah, Florida 33012, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Accelovance
    Melbourne, Florida 32934, United States
  • Accelovance
    Melbourne, Florida 32935, United States
  • North Georgia Clinical Research Center
    Dalton, Georgia 30721, United States
  • Northern Illinois Research Associates
    DeKalb, Illinois 60115, United States
  • Northpoint Pediatrics
    Indianapolis, Indiana 46256, United States
  • Accelovance, Inc.
    Mishawaka, Indiana 46545, United States
  • Optimal Research, LLC
    Mishawaka, Indiana 46545, United States
  • Nassim, McMonigle, Mescia & Associates
    New Albany, Indiana 47150, United States
  • Augusta Family Practice
    Augusta, Kansas 67010, United States
  • Heartland Research Associates, LLC
    Augusta, Kansas 67010, United States
  • Heartland Research Associates, LLC
    Newton, Kansas 67114, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67205, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • Kentucky Pediatric/Adult Research
    Bardstown, Kentucky 40004, United States
  • Bluegrass Clinical Research, Inc.
    Louisville, Kentucky 40291, United States
  • Central Kentucky Research Associates, Inc.
    MT. Sterling, Kentucky 40353, United States
  • Mt. Sterling Pediatrics
    Mt. Sterling, Kentucky 40353, United States
  • Pedia Research, LLC
    Owensboro, Kentucky 42301, United States
  • David B. Ware, MD
    Eunice, Louisiana 70535, United States
  • Horizon Research Group of Opelousas, LLC
    Eunice, Louisiana 70535, United States
  • ACC Pediatric Research
    Haughton, Louisiana 71037, United States
  • Benchmark Research
    Metairie, Louisiana 70006, United States
  • Southwestern Medical Clinic Lakeland HealthCare Affiliate
    Niles, Michigan 49120, United States
  • Allina Health Bandana Square Clinic
    Saint Paul, Minnesota 55108, United States
  • Sundance Clinical Research, LLC
    Saint Louis, Missouri 63141, United States
  • Bellevue Urgent Care
    Bellevue, Nebraska 68005, United States
  • Pioneer Clinical Research, LLC
    Bellevue, Nebraska 68005, United States
  • Creighton University Medical Center
    Omaha, Nebraska 68131, United States
  • Meridian Clinical Research, Llc
    Omaha, Nebraska 68134, United States
  • Winthrop Division of Pediatric Infectious Diseases
    Mineola, New York 11501, United States
  • Winthrop Pediatric Associates
    Mineola, New York 11501, United States
  • Winthrop University Pharmacy
    Mineola, New York 11501, United States
  • Winthrop-University Hospital - Clinical Trials Center
    Mineola, New York 11501, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • Asheboro Research Associates
    Asheboro, North Carolina 27203, United States
  • Cary Pediatric Center
    Cary, North Carolina 27518, United States
  • Capitol Pediatrics & Adolescent Center PLLC
    Raleigh, North Carolina 27609, United States
  • Dr. Shelly David Senders, MD Inc. dba Senders Pediatrics
    Cleveland, Ohio 44121, United States
  • Dayton Clinical Research
    Dayton, Ohio 45406, United States
  • Ohio Pediatric Research Association
    Dayton, Ohio 45414, United States
  • Ohio Pediatrics, Inc.
    Dayton, Ohio 45414, United States
  • Liberty Family Practice
    Erie, Pennsylvania 16508, United States
  • Preferred Primary Care Physicians, Inc.
    Uniontown, Pennsylvania 15401, United States
  • PEAK Research, LLC
    Upper St. Clair, Pennsylvania 15241, United States
  • Holston Medical Group - Suite 3B
    Kingsport, Tennessee 37660, United States
  • Holston Medical Group Laboratory
    Kingsport, Tennessee 37660, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Cumberland Pediatrics Associates
    Lebanon, Tennessee 37087, United States
  • Pediatric Research of Charlottesville, LLC
    Charlottesville, Virginia 22902, United States
  • Pediatric Research of Charlottesville
    Charlottesville, Virginia 22902, United States
  • Advanced Pediatrics
    Vienna, Virginia 22180, United States
  • The Vancouver Clinic
    Vancouver, Washington 98664, United States
  • Medicor Research Inc.
    Sudbury, Ontario P3E 1H5, Canada
  • Dr. Hartley Garfield Medicine Professional Corporation
    Toronto, Ontario M5G 1N8, Canada
  • Diex Research Sherbrooke Inc.
    Sherbrooke, Quebec J1H 1Z1, Canada
  • Clinique Medicale St-Louis (recherche) Inc.
    Quebec, G1W 4R4, Canada
  • ALPHA Recherche Clinique
    Quebec, G3K 2P8, Canada
  • Ordinace praktickeho lekare pro deti a dorost
    Brandys nad Labem - Stara Boleslav, 25001, Czech Republic
  • Fakultni nemocnice Hradec Kralove, Klinika infekcnich nemoci,Centrum ockovani a cestovni mediciny
    Hradec Kralove, 500 05, Czech Republic
  • Ordinace praktickeho lekare pro deti a dorost
    Hradec Kralove, 50002, Czech Republic
  • Ordinace praktickeho lekare pro deti a dorost
    Jindrichuv Hradec, 37701, Czech Republic
  • Ordinace praktickeho lekare pro deti a dorost
    Odolena Voda, 25070, Czech Republic
  • MUDr. Elena Adamkova
    Pardubice, 53002, Czech Republic
  • Zdravotnicke stredisko Dubina v.o.s.
    Pardubice, 53012, Czech Republic
  • Ordinace praktickeho lekare pro deti a dorost
    Praha 6, 16000, Czech Republic
  • Helsinki East Vaccine Research Clinic
    Helsinki, 00930, Finland
  • Jarvenpaa Vaccine Research Clinic
    Jarvenpaa, 04400, Finland
  • Oulu Vaccine Research Clinic
    Oulu, 90220, Finland
  • Vantaa East Vaccine Research Clinic
    Vantaa, 01300, Finland
  • Central Laboratory and Vaccination Centre, Stiftung Juliusspital
    Wuerzburg, Bavaria 97070, Germany
  • Kinderarztpraxis Dr. Thomas Adelt
    Bramsche, 49565, Germany
  • Gemeinschaftspraxis für Kinder- und Jugendmedizin Dres. Behre, Burgert, Günkel
    Kehl, 77694, Germany
  • Dipartimento di Scienze della Salute
    Genova, 16132, Italy
  • UOC di Pediatria 1
    Milano, 20122, Italy
  • Azienda Sanitaria Provinciale di Ragusa
    Ragusa, 97100, Italy
  • Azienda Ospedaliero Universitaria di Sassari
    Sassari, 07100, Italy
  • Servizio di Igiene e Sanita Pubblica
    Sassari, 07100, Italy
  • oddzial Neuroinfekcji i Neurologii Dzieciecel, Krakowski Szpital Specjalistyczny im.J ana Pawla II
    Krakow, Malopolska 31-202, Poland
  • Wojewodzka Poradnia Szczepien Ochronnych
    Krakow, Malopolska 31-202, Poland
  • Prywatny Gabinet Lekarski dr n med. Jerzy Brzostek
    Debica, 39-200, Poland
  • NZOZ Praktyka Lekarza Rodzinnego lek.med. Agata Slawin
    Kielczow, 55-093, Poland
  • NZOZ Praktyka Lekarza Rodzinnego Eskulap Sp.z o.o.
    Lublin, 20-044, Poland
  • NZOZ Praktyka Lekarza Rodzinnego Eskulap Sp.z o.o. ul.
    Lunlin, 20-044, Poland
  • NZLA Michalkowice Jarosz i Partnerzy Spolka Lekarska
    Siemianowice Slaskie, 41-103, Poland
  • NZOZ Praktyka Lekarza Rodzinnego Beata Stecka
    Wroclaw, 50-452, Poland
  • NIHR Wellcome Trust Clinical Research Facility
    Southampton, Hampshire SO16 6YD, United Kingdom
  • University of Bristol, Clinical Research and Imaging Centre
    Bristol, BS2 8DX, United Kingdom
  • St. George's University of London**
    London, SW17 ORE, United Kingdom
  • Oxford Vaccine Group, University of Oxford
    Oxford, OX3 7LE, United Kingdom
09

References and documents

Publications

  • Beeslaar J, Mather S, Absalon J, Eiden JJ, York LJ, Crowther G, Maansson R, Maguire JD, Peyrani P, Perez JL. Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older. Vaccine. 2022 Mar 15;40(12):1872-1878. doi: 10.1016/j.vaccine.2022.01.046. Epub 2022 Feb 11. PubMed 35164991 ↗
  • Beeslaar J, Absalon J, Anderson AS, Eiden JJ, Balmer P, Harris SL, Jones TR, O'Neill RE, Pregaldien JL, Radley D, Maansson R, Ginis J, Srivastava A, Perez JL. MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies. Infect Dis Ther. 2020 Sep;9(3):641-656. doi: 10.1007/s40121-020-00319-0. Epub 2020 Jul 22. PubMed 32700260 ↗
  • Beeslaar J, Peyrani P, Absalon J, Maguire J, Eiden J, Balmer P, Maansson R, Perez JL. Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data. Infect Dis Ther. 2020 Sep;9(3):625-639. doi: 10.1007/s40121-020-00322-5. Epub 2020 Jul 17. PubMed 32681472 ↗
  • Ostergaard L, Vesikari T, Absalon J, Beeslaar J, Ward BJ, Senders S, Eiden JJ, Jansen KU, Anderson AS, York LJ, Jones TR, Harris SL, O'Neill R, Radley D, Maansson R, Pregaldien JL, Ginis J, Staerke NB, Perez JL; B1971009 and B1971016 Trial Investigators. A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults. N Engl J Med. 2017 Dec 14;377(24):2349-2362. doi: 10.1056/NEJMoa1614474. PubMed 29236639 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2013
First posted
Apr 12, 2013
Start
Apr 2013
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Results first posted
Jun 14, 2016
Last update
Jun 14, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01830855
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 12, 2013
Start date
Apr 2013
Primary completion
Apr 2015
Completion
Apr 2015
Results posted
Jun 14, 2016
Last update
Jun 14, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: MenB-FHbp vaccine · 4CMenB vaccine

Start the discussion